Did you mean aromatase inhibitor?
Displaying drugs 676 - 700 of 2444 in total
Lumacaftor
Lumacaftor is a drug used in combination with DB08820 as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic...
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) …
Cisapride
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (strong) …
Ademetionine
Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Approved
Investigational
Nutraceutical
Matched Categories: … Cytochrome P-450 CYP2E1 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2E1 Inhibitors (weak) …
Oxamniquine
An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp. Oxamniquine causes worms to shift from the mesenteric veins to the liver where the male worms are retained; the female worms return to the mesentery, but can no longer release eggs. (From Martidale, The Extra Pharmacopoeia,...
Approved
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Cholic Acid
A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. [PubChem]
Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid...
Approved
Matched Categories: … BSEP/ABCB11 Inhibitors ... OAT3/SLC22A8 Inhibitors ... OATP1B1/SLCO1B1 Inhibitors …
Carfilzomib
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
Approved
Investigational
Matched Categories: … Proteasome Inhibitors ... P-glycoprotein inhibitors …
Ozenoxacin
To date, ozenoxacin has been used in trials studying the treatment of impetigo.
As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by Staphylococccus aureus or Streptococcus pyogenes in adult and pediatric patients...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors …
Testosterone cypionate
Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. It was developed by the company Pharmacia and Upjohn and FDA approved on July 25,...
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Thyroxine-binding globulin inhibitors …
Amphetamine
Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first...
Approved
Illicit
Investigational
Matched Categories: … Dopamine Uptake Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Neurotransmitter Uptake Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors (weak) …
Acyclovir
Acyclovir is a deoxynucleoside analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis.[L7303,L7315,L7318,L7321,L7324,L7327] Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old. Acyclovir was granted FDA...
Approved
Matched Categories: … OCT1 inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors ... Reverse Transcriptase Inhibitors ... Nucleic Acid Synthesis Inhibitors …
Alosetron
Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer...
Approved
Withdrawn
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2E1 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (moderate) ... Cytochrome P-450 CYP2E1 Inhibitors (moderate) …
Secukinumab
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan...
Approved
Matched Categories: … Interleukin Inhibitors ... Interleukin-17, antagonists & inhibitors …
Mazindol
Mazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. Mazindol is only approved in the United States for the treatment of Duchenne...
Approved
Investigational
Matched Categories: … Adrenergic Uptake Inhibitors ... Dopamine Uptake Inhibitors ... Neurotransmitter Uptake Inhibitors ... Combined Inhibitors of Serotonin/Norepinephrine Reuptake …
Lanreotide
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, Ipsen...
Approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (weak) …
Interferon alfa-2a
Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Epirubicin
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Approved
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors …
Echothiophate
A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Approved
Matched Categories: … Enzyme Inhibitors ... Cholinesterase Inhibitors …
Rutin
A flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility.
Approved
Experimental
Investigational
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Tislelizumab
Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis. By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated...
Approved
Investigational
Matched Categories: … Immune Checkpoint Inhibitors ... PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors ... PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors …
Risdiplam
Risdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). It increases systemic SMN protein concentrations by improving the efficiency of SMN2 gene transcription. This mechanism of action is similar to its predecessor nusinersen, the biggest difference being their route of administration: nusinersen...
Approved
Investigational
Matched Categories: … MATE inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors …
Retifanlimab
Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. Other monoclonal...
Approved
Investigational
Matched Categories: … Immune Checkpoint Inhibitors ... PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors ... PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors …
Tamoxifen
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers...
Approved
Matched Categories: … BSEP/ABCB11 Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …
Sulfamethoxazole
Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and...
Approved
Matched Categories: … BSEP/ABCB11 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Peginterferon alfa-2b
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (weak) ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Spironolactone
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837, A178246] It is indicated to treat several conditions, including...
Approved
Matched Categories: … Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors (moderate) …
Displaying drugs 676 - 700 of 2444 in total